HC Wainwright reissued their buy rating on shares of Emergent Biosolutions (NYSE:EBS – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has a $10.00 price target on the biopharmaceutical company’s stock.
Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. began coverage on shares of Emergent Biosolutions in a report on Friday, August 21st. They issued an “underweight” rating on the stock. Benchmark restated a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. UBS Group reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Weiss Ratings upgraded shares of Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, August 21st. Finally, Zacks Research raised shares of Emergent Biosolutions to a “hold” rating in a research report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.
Emergent Biosolutions Stock Performance
Emergent Biosolutions (NYSE:EBS – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.68. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%.The business had revenue of $234.30 million for the quarter, compared to analysts’ expectations of $177.50 million. As a group, sell-side analysts forecast that Emergent Biosolutions will post 0.13 earnings per share for the current year.
Insiders Place Their Bets
In related news, SVP Paul Williams sold 3,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the sale, the senior vice president directly owned 159,098 shares in the company, valued at approximately $1,336,423.20. The trade was a 1.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.00% of the company’s stock.
Hedge Funds Weigh In On Emergent Biosolutions
A number of institutional investors and hedge funds have recently added to or reduced their stakes in EBS. Franklin Resources Inc. raised its position in shares of Emergent Biosolutions by 2.3% in the fourth quarter. Franklin Resources Inc. now owns 78,945 shares of the biopharmaceutical company’s stock valued at $976,000 after purchasing an additional 1,764 shares during the period. SG Americas Securities LLC boosted its holdings in Emergent Biosolutions by 4.6% in the 1st quarter. SG Americas Securities LLC now owns 42,394 shares of the biopharmaceutical company’s stock worth $352,000 after buying an additional 1,865 shares during the period. Deutsche Bank AG boosted its holdings in Emergent Biosolutions by 1.1% in the 4th quarter. Deutsche Bank AG now owns 181,744 shares of the biopharmaceutical company’s stock worth $2,246,000 after buying an additional 1,941 shares during the period. Values First Advisors Inc. boosted its holdings in Emergent Biosolutions by 0.9% in the 1st quarter. Values First Advisors Inc. now owns 307,880 shares of the biopharmaceutical company’s stock worth $2,555,000 after buying an additional 2,834 shares during the period. Finally, First Trust Advisors LP grew its stake in Emergent Biosolutions by 19.6% in the 1st quarter. First Trust Advisors LP now owns 17,357 shares of the biopharmaceutical company’s stock valued at $144,000 after buying an additional 2,848 shares in the last quarter. Institutional investors own 78.40% of the company’s stock.
About Emergent Biosolutions
Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.
Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.
Read More
- Five stocks we like better than Emergent Biosolutions
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.
